1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
    Neuronal Signaling
  3. Calcium Channel

Calcium Channel

Ca2+ channels; Ca channels

Calcium channel is an ion channel which displays selective permeability to calcium ions. It is sometimes synonymous as voltage-dependent calcium channel, although there are also ligand-gated calcium channels. Voltage-gated calcium (CaV) channels catalyse rapid, highly selective influx of Ca2+ into cells despite a 70-fold higher extracellular concentration of Na+. Some calcium channel blockers have the added benefit of slowing your heart rate, which can further reduce blood pressure, relieve chest pain (angina) and control an irregular heartbeat.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-116072
    Antiarrhythmic agent-2
    Inhibitor
    Antiarrhythmic agent-2 is a nonspecific Ca2+ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias.
    Antiarrhythmic agent-2
  • HY-122201
    NSC156529
    Antagonist
    NSC156529 is a potent T-type calcium-channel antagonist. NSC156529 shows inhibits on Cav3.1 and Cav3.2 and o Cav3.3 without effect. NSC156529 has the potential for the research of neuropsychic and genital system diseases.
    NSC156529
  • HY-172570
    D-myo-Inositol-1,2,3,5-tetraphosphate tetrasodium
    D-myo-inositol-1,2,3,5-tetraphosphate (Ins(1,2,3,5,6)-P5) tetrasodium is one of the Inositol phosphate isomers and can act as a soluble second messenger to participate in cellular calcium signaling.
    D-myo-Inositol-1,2,3,5-tetraphosphate tetrasodium
  • HY-B0280S1
    Ranolazine-d8
    Inhibitor 99.9%
    Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
    Ranolazine-d<sub>8</sub>
  • HY-180443
    AT1R antagonist 4
    AT1R antagonist 4 (Example 26) is an AT1R antagonist. AT1R antagonist 4 shows excellent antagonistic activity against calcium influx in cells stably expressing AT1 receptors and ETA receptors. AT1R antagonist 4 can be used in kidney disease research.
    AT1R antagonist 4
  • HY-B0166AR
    L-Ascorbic acid sodium salt (Standard)
    Inhibitor
    L-Ascorbic acid (sodium salt) (Standard) is the analytical standard of L-Ascorbic acid (sodium salt). This product is intended for research and analytical applications. L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor.
    L-Ascorbic acid sodium salt (Standard)
  • HY-B0265R
    Nimodipine (Standard)
    Inhibitor
    Nimodipine (Standard) is the analytical standard of Nimodipine. This product is intended for research and analytical applications. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders.
    Nimodipine (Standard)
  • HY-B1090R
    Cinnarizine (Standard)
    Inhibitor
    Cinnarizine (Standard) is the analytical standard of Cinnarizine. This product is intended for research and analytical applications.
    Cinnarizine (Standard)
  • HY-14275S
    Verapamil-d3
    Antagonist
    Verapamil-d3 ((±)-Verapamil-d3) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research.
    Verapamil-d<sub>3</sub>
  • HY-W788583
    Inositol 1,3-bisphosphate sodium
    Inositol 1,3-bisphosphate sodium is one of the many inositol phosphate (InsP) isomers that could act as small, soluble second messengers in the transmission of cellular signals.
    Inositol 1,3-bisphosphate sodium
  • HY-B0419R
    Manidipine (Standard)
    Inhibitor
    Manidipine (Standard) is the analytical standard of Manidipine. This product is intended for research and analytical applications. Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy.
    Manidipine (Standard)
  • HY-183871
    WMS-1410
    WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain.
    WMS-1410
  • HY-118136
    CGP 28392
    Activator
    CGP 28392 is an activator for calcium channel, and reactivates the oxygen evolution in calcium-deficient photosystem II (PS II) particles.
    CGP 28392
  • HY-108981
    CERM11956
    Inhibitor
    CERM11956 is a potent anti-ischaemic agent. CERM11956 is a derivative of bepridil(HY-16952).
    CERM11956
  • HY-103309R
    ML218 (Standard)
    Inhibitor
    ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier.
    ML218 (Standard)
  • HY-17403R
    Manidipine dihydrochloride (Standard)
    Inhibitor
    Manidipine (dihydrochloride) (Standard) is the analytical standard of Manidipine (dihydrochloride). This product is intended for research and analytical applications. Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC50 = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection.
    Manidipine dihydrochloride (Standard)
  • HY-14744D
    Levamlodipine besylate Hemipentahydrate
    Inhibitor
    Levamlodipine besylate Hemipentahydrate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate Hemipentahydrate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate Hemipentahydrate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate Hemipentahydrate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate Hemipentahydrate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate Hemipentahydrate can be used in research related to hypertension and atherosclerosis.
    Levamlodipine besylate Hemipentahydrate
  • HY-B0612C
    (R)-Lercanidipine
    Inhibitor
    (R)-Lercanidipine is the R-enantiomer of Lercanidipine. (R)-lercanidipine is a calcium channel blocker.
    (R)-Lercanidipine
  • HY-17404S1
    Cilnidipine-d4
    Inhibitor
    Cilnidipine-d4 (FRC-8653-d4) is deuterium labeled Cilnidipine. Cilnidipine is a long-acting, second-generation dihydropyridine Ca2+-channel blocker on L and N-type Ca2+ channel. Antihypertensive effects.
    Cilnidipine-d<sub>4</sub>
  • HY-10805R
    Almorexant (Standard)
    Inhibitor
    Almorexant (Standard) is the analytical standard of Almorexant. This product is intended for research and analytical applications. Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca2+ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .
    Almorexant (Standard)
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.